효소 DNA 합성 시장 규모, 점유율, 동향 분석 리포트 : 서비스별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Enzymatic DNA Synthesis Market Summary

The global enzymatic DNA synthesis market size was estimated at USD 292.9 million in 2024, is projected to reach USD 2,444.7 million by 2033, expanding at a CAGR of 26.65% from 2025 to 2033. Owing to advancements in technology, rising demand for precision medicine, increased research in synthetic biology, and greater funding for genetic research and biotechnology are anticipated to drive the growth of the enzymatic DNA synthesis market.

Automation Breakthrough Expands Scope of Enzymatic DNA Applications

Moreover, the expanding biopharmaceutical sector, with its focus on innovative drug development and genetic research, is further propelling the enzymatic DNA synthesis market over the forecast period. Enzymatic DNA synthesis continues to push the boundaries of molecular manufacturing, with recent breakthroughs demonstrating its potential beyond traditional biotechnology. A pioneering development featured in PNAS introduces the DNA-DISK platform, which integrates enzymatic single-nucleotide DNA synthesis and sequencing with digital microfluidics. This end-to-end, fully automated system encodes digital data into DNA strands using terminal deoxynucleotidyl transferase (TdT), offering a streamlined and scalable alternative to conventional synthesis and sequencing workflows. By eliminating harsh chemicals and enabling synthesis in aqueous environments, this platform aligns with the global shift toward safer, faster, and more sustainable production methods.

The innovation lies in its ability to automate the entire DNA data storage cycle-from writing to reading-within a compact and digitally controlled setup. The system's enzymatic precision allows for single-base additions, essential for encoding data accurately. This development reinforces enzymatic DNA synthesis as a flexible tool that can support decentralized synthesis models, especially in domains that require high-throughput and precision, such as bioinformatics and digital archiving. Companies in the sector, including DNA Script, Molecular Assemblies, and Ansa Biotechnologies, are already pursuing similar technological directions to meet demand for advanced, application-specific synthesis platforms.

This advancement reflects the evolving scope and commercial potential of enzymatic synthesis technologies. As demand grows for miniaturized, sustainable, and automated systems capable of operating beyond genomic applications, innovations such as DNA-DISK signal a significant market opportunity. DNA-based data storage-valued for its density, longevity, and eco-efficiency-is gaining traction as a frontier technology. The ability to synthesize and process DNA sequences autonomously opens doors to new collaborations and market expansion, positioning enzymatic synthesis as a critical enabler of next-generation molecular solutions across synthetic biology, data science, and decentralized biomanufacturing.

Scalable DNA Innovation Reshaping the Future of Synthetic Biology

Enzymatic DNA synthesis (EDS) is rapidly emerging as a transformative alternative to traditional chemical methods, addressing long-standing limitations in length, fidelity, and environmental sustainability. While phosphoramidite chemistry has dominated DNA synthesis for decades, it struggles to efficiently produce sequences beyond 300 bases due to cumulative cycle inefficiencies and high error rates. In contrast, EDS uses terminal deoxynucleotidyl transferase (TdT) to add nucleotides under mild, aqueous conditions, enabling high-purity synthesis of longer DNA fragments. This leap in technical capability is crucial for supporting advanced applications in genomics, gene editing, synthetic biology, and mRNA-based drug development.

From a commercial standpoint, the shift toward EDS is unlocking new growth avenues across the life sciences sector. The ability to produce long, accurate, and sequence-diverse DNA constructs quickly and sustainably offers a competitive edge in high-throughput R&D and decentralized biomanufacturing. Companies pioneering this shift are gaining strategic traction by offering benchtop instruments, on-demand synthesis services, and early-access programs tailored for use in therapeutics, vaccine development, and next-generation bioengineering. As industries prioritize faster iteration cycles, reduced reliance on outsourcing, and greener technologies, enzymatic DNA synthesis is redefining the competitive landscape, positioning itself as a cornerstone of the evolving synthetic biology ecosystem.

Global Enzymatic DNA Synthesis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global enzymatic DNA synthesis market report based on services, application, end use, and region.

• Services Outlook (Revenue, USD Million, 2021 - 2033)
• Oligonucleotide Synthesis
• Gene Synthesis
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Synthetic Biology
• Genetic Engineering
• Vaccine Development
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Companies
• Academic & Research Institutes
• Contract Research Organizations
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Chile
• MEA
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Services
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Enzymatic DNA Synthesis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing biopharmaceutical industry
    • 3.2.1.2. Rising demand for precision medicine
    • 3.2.1.3. Increasing research in synthetic biology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs of enzymatic DNA synthesis
• 3.3. Enzymatic DNA Synthesis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Enzymatic DNA Synthesis Market: Services Estimates & Trend Analysis

• 4.1. Services Segment Dashboard
• 4.2. Global Enzymatic DNA Synthesis Market Services Movement Analysis
• 4.3. Global Enzymatic DNA Synthesis Market Size & Trend Analysis, by Services, 2021 to 2033 (USD Million)
• 4.4. Oligonucleotide Synthesis
  • 4.4.1. Oligonucleotide synthesis market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Gene Synthesis
  • 4.5.1. Gene synthesis market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Enzymatic DNA Synthesis Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Enzymatic DNA Synthesis Market Application Movement Analysis
• 5.3. Global Enzymatic DNA Synthesis Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Synthetic Biology
  • 5.4.1. Synthetic biology market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Vaccine Development
  • 5.5.1. Vaccine development market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Genetic Engineering
  • 5.6.1. Genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Enzymatic DNA Synthesis Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global Enzymatic DNA Synthesis Market End Use Movement Analysis
• 6.3. Global Enzymatic DNA Synthesis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Biopharmaceutical Companies
  • 6.4.1. Biopharmaceutical companies market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Contract Research Organizations
  • 6.6.1. Contract research organizations market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Enzymatic DNA Synthesis Market: Regional Estimates & Trend Analysis by Services, Application, and End Use

• 7.1. Regional Market Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.9. Denmark
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. Chile
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Chile market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Telesis Bio Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Twist Bioscience Corporation
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. GenScript Biotech Corp.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Evonetix
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Ansa Biotechnologies, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Camena Bio
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Molecular Assemblies
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. DNA Script
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Touchlight
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Kern Systems
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives